img

Global Novel Coronavirus (COVID-19) Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Novel Coronavirus (COVID-19) Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Novel Coronavirus (COVID-19) Vaccine market size was US$ million in 2023 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the forecast period 2023-2033. Fully considering the economic change by this health crisis, DNA accounting for % of the Novel Coronavirus (COVID-19) Vaccine global market in 2023, is projected to value US$ million by 2033, growing at a revised % CAGR from 2023 to 2033. While Mild Symptom Patient segment is altered to an % CAGR throughout this forecast period.
The global key companies of Novel Coronavirus (COVID-19) Vaccine include Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune and Vaxart, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
The United States Novel Coronavirus (COVID-19) Vaccine market size was US$ million in 2023, while China size was US$ million. The proportion of the United States was % in 2023, while China percentage was %, and it is predicted that China share will reach % in 2033, trailing a CAGR of % through the analysis period. As for the Europe Novel Coronavirus (COVID-19) Vaccine landscape, Germany is projected to reach US$ million by 2033. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Novel Coronavirus (COVID-19) Vaccine market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Novel Coronavirus (COVID-19) Vaccine market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Novel Coronavirus (COVID-19) Vaccine market. Readers of the report can become informed about current and future trends of the global Novel Coronavirus (COVID-19) Vaccine market and how they will impact market growth during the forecast period.



By Company


Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Segment by Type
DNA
RNA
Others

Segment by Application


Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Novel Coronavirus (COVID-19) Vaccine in global and regional level.
Chapter 3Detailed analysis of Novel Coronavirus (COVID-19) Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Novel Coronavirus (COVID-19) Vaccine revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 DNA
1.2.3 RNA
1.2.4 Others
1.3 Market by Application
1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Application: 2018 VS 2023 VS 2033
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
2.2 Novel Coronavirus (COVID-19) Vaccine Market Size across Key Geographies Worldwide: 2018 VS 2023 VS 2033
2.3 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023)
2.4 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast by Region (2024-2033)
2.5 Global Top 10 Novel Coronavirus (COVID-19) Vaccine Countries Ranking by Market Size
3 Novel Coronavirus (COVID-19) Vaccine Competitive by Company
3.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players
3.1.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2018-2023)
3.1.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2018-2023)
3.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Novel Coronavirus (COVID-19) Vaccine Revenue
3.4 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio
3.4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023
3.5 Global Key Players of Novel Coronavirus (COVID-19) Vaccine Head office and Area Served
3.6 Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Product and Application
3.7 Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Type
4.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Revenue by Type (2018-2023)
4.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Revenue by Type (2024-2033)
5 Global Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Application
5.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Application (2018-2023)
5.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023)
6.2 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2033)
6.3 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2033)
6.4 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2033)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023)
7.2 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2033)
7.3 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2033)
7.4 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2033)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023)
8.2 Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2033)
8.3 Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2033)
8.4 Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2018-2033)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023)
9.2 Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2033)
9.3 Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2033)
9.4 Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2033)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023)
10.2 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2033)
10.3 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2033)
10.4 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2033)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Inovio Pharmaceuticals
11.1.1 Inovio Pharmaceuticals Company Details
11.1.2 Inovio Pharmaceuticals Business Overview
11.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products and Services
11.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.1.5 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.1.6 Inovio Pharmaceuticals Recent Development
11.2 Takis Biotech (Evvivax)
11.2.1 Takis Biotech (Evvivax) Company Details
11.2.2 Takis Biotech (Evvivax) Business Overview
11.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Products and Services
11.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.2.5 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.2.6 Takis Biotech (Evvivax) Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Details
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Products and Services
11.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.3.5 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.3.6 Zydus Cadila Recent Development
11.4 Codagenix, Inc.
11.4.1 Codagenix, Inc. Company Details
11.4.2 Codagenix, Inc. Business Overview
11.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Products and Services
11.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.4.5 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.4.6 Codagenix, Inc. Recent Development
11.5 GeoVax, Inc.
11.5.1 GeoVax, Inc. Company Details
11.5.2 GeoVax, Inc. Business Overview
11.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Products and Services
11.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.5.5 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.5.6 GeoVax, Inc. Recent Development
11.6 Bravovax
11.6.1 Bravovax Company Details
11.6.2 Bravovax Business Overview
11.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Products and Services
11.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.6.5 Bravovax Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.6.6 Bravovax Recent Development
11.7 Janssen Pharmaceutical Companies
11.7.1 Janssen Pharmaceutical Companies Company Details
11.7.2 Janssen Pharmaceutical Companies Business Overview
11.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Products and Services
11.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.7.5 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.7.6 Janssen Pharmaceutical Companies Recent Development
11.8 Altimmune
11.8.1 Altimmune Company Details
11.8.2 Altimmune Business Overview
11.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Products and Services
11.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.8.5 Altimmune Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.8.6 Altimmune Recent Development
11.9 Vaxart
11.9.1 Vaxart Company Details
11.9.2 Vaxart Business Overview
11.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Products and Services
11.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.9.5 Vaxart Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.9.6 Vaxart Recent Development
11.10 CanSino Biologics
11.10.1 CanSino Biologics Company Details
11.10.2 CanSino Biologics Business Overview
11.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Products and Services
11.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.10.5 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
11.10.6 CanSino Biologics Recent Development
11.11 ExpreS2ion Biotechnologies ApS
11.11.1 ExpreS2ion Biotechnologies ApS Company Details
11.11.2 ExpreS2ion Biotechnologies ApS Business Overview
11.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Products and Services
11.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.11.5 ExpreS2ion Biotechnologies ApS Recent Development
11.12 Clover Biopharmaceuticals
11.12.1 Clover Biopharmaceuticals Company Details
11.12.2 Clover Biopharmaceuticals Business Overview
11.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products and Services
11.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.12.5 Clover Biopharmaceuticals Recent Development
11.13 GSK
11.13.1 GSK Company Details
11.13.2 GSK Business Overview
11.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Products and Services
11.13.4 GSK Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.13.5 GSK Recent Development
11.14 Vaxil Bio Ltd.
11.14.1 Vaxil Bio Ltd. Company Details
11.14.2 Vaxil Bio Ltd. Business Overview
11.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Products and Services
11.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.14.5 Vaxil Bio Ltd. Recent Development
11.15 Generex
11.15.1 Generex Company Details
11.15.2 Generex Business Overview
11.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Products and Services
11.15.4 Generex Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.15.5 Generex Recent Development
11.16 Novavax, Inc.
11.16.1 Novavax, Inc. Company Details
11.16.2 Novavax, Inc. Business Overview
11.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Products and Services
11.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.16.5 Novavax, Inc. Recent Development
11.17 Sanofi Pasteur
11.17.1 Sanofi Pasteur Company Details
11.17.2 Sanofi Pasteur Business Overview
11.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Products and Services
11.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.17.5 Sanofi Pasteur Recent Development
11.18 Baylor
11.18.1 Baylor Company Details
11.18.2 Baylor Business Overview
11.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Products and Services
11.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.18.5 Baylor Recent Development
11.19 iBio, Inc.
11.19.1 iBio, Inc. Company Details
11.19.2 iBio, Inc. Business Overview
11.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Products and Services
11.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.19.5 iBio, Inc. Recent Development
11.20 Moderna, Inc.
11.20.1 Moderna, Inc. Company Details
11.20.2 Moderna, Inc. Business Overview
11.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Products and Services
11.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.20.5 Moderna, Inc. Recent Development
11.21 Curevac
11.21.1 Curevac Company Details
11.21.2 Curevac Business Overview
11.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Products and Services
11.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.21.5 Curevac Recent Development
11.22 ImmunoPrecise
11.22.1 ImmunoPrecise Company Details
11.22.2 ImmunoPrecise Business Overview
11.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Products and Services
11.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.22.5 ImmunoPrecise Recent Development
12 Novel Coronavirus (COVID-19) Vaccine Market Dynamics
12.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends
12.2 Novel Coronavirus (COVID-19) Vaccine Market Drivers
12.3 Novel Coronavirus (COVID-19) Vaccine Market Challenges
12.4 Novel Coronavirus (COVID-19) Vaccine Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2023 VS 2033
Table 2. Key Players of DNA
Table 3. Key Players of RNA
Table 4. Key Players of Others
Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Application (US$ Million), 2018 VS 2023 VS 2033
Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2023 VS 2033
Table 7. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Region (2024-2033) & (US$ Million)
Table 9. Global Novel Coronavirus (COVID-19) Vaccine Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Table 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2018-2023)
Table 12. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
Table 13. Ranking of Global Top Novel Coronavirus (COVID-19) Vaccine Companies by Revenue (US$ Million) in 2023
Table 14. Global 5 Largest Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 15. Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Headquarters and Area Served
Table 16. Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Product and Application
Table 17. Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 20. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2023)
Table 21. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 22. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2024-2033)
Table 23. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 24. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2023)
Table 25. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 26. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2024-2033)
Table 27. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023) & (US$ Million)
Table 28. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 29. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 30. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 31. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 32. North America Novel Coronavirus (COVID-19) Vaccine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 33. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 34. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2024-2033) & (US$ Million)
Table 35. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023) & (US$ Million)
Table 36. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 37. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 38. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 39. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 40. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 41. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 42. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2024-2033) & (US$ Million)
Table 43. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023) & (US$ Million)
Table 44. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 45. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 46. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 47. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 48. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 49. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 50. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2024-2033) & (US$ Million)
Table 51. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023) & (US$ Million)
Table 52. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 53. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 54. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 55. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 56. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 57. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 58. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2024-2033) & (US$ Million)
Table 59. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2021-2023) & (US$ Million)
Table 60. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 61. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2024-2033) & (US$ Million)
Table 62. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 63. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2024-2033) & (US$ Million)
Table 64. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 65. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 66. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2024-2033) & (US$ Million)
Table 67. Inovio Pharmaceuticals Company Details
Table 68. Inovio Pharmaceuticals Business Overview
Table 69. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 70. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 71. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 72. Inovio Pharmaceuticals Recent Development
Table 73. Takis Biotech (Evvivax) Company Details
Table 74. Takis Biotech (Evvivax) Business Overview
Table 75. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 76. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 77. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 78. Takis Biotech (Evvivax) Recent Development
Table 79. Zydus Cadila Company Details
Table 80. Zydus Cadila Business Overview
Table 81. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 82. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 83. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 84. Zydus Cadila Recent Development
Table 85. Codagenix, Inc. Company Details
Table 86. Codagenix, Inc. Business Overview
Table 87. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 88. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 89. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 90. Codagenix, Inc. Recent Development
Table 91. GeoVax, Inc. Company Details
Table 92. GeoVax, Inc. Business Overview
Table 93. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 94. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 95. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 96. GeoVax, Inc. Recent Development
Table 97. Bravovax Company Details
Table 98. Bravovax Business Overview
Table 99. Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 100. Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 101. Bravovax Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 102. Bravovax Recent Development
Table 103. Janssen Pharmaceutical Companies Company Details
Table 104. Janssen Pharmaceutical Companies Business Overview
Table 105. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 106. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 107. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 108. Janssen Pharmaceutical Companies Recent Development
Table 109. Altimmune Company Details
Table 110. Altimmune Business Overview
Table 111. Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 112. Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 113. Altimmune Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 114. Altimmune Recent Development
Table 115. Vaxart Company Details
Table 116. Vaxart Business Overview
Table 117. Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 118. Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 119. Vaxart Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 120. Vaxart Recent Development
Table 121. CanSino Biologics Company Details
Table 122. CanSino Biologics Business Overview
Table 123. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 124. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 125. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine SWOT Analysis
Table 126. CanSino Biologics Recent Development
Table 127. ExpreS2ion Biotechnologies ApS Company Details
Table 128. ExpreS2ion Biotechnologies ApS Business Overview
Table 129. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 130. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 131. ExpreS2ion Biotechnologies ApS Recent Development
Table 132. Clover Biopharmaceuticals Company Details
Table 133. Clover Biopharmaceuticals Business Overview
Table 134. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 135. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 136. Clover Biopharmaceuticals Recent Development
Table 137. GSK Company Details
Table 138. GSK Business Overview
Table 139. GSK Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 140. GSK Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 141. GSK Recent Development
Table 142. Vaxil Bio Ltd. Company Details
Table 143. Vaxil Bio Ltd. Business Overview
Table 144. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 145. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 146. Vaxil Bio Ltd. Recent Development
Table 147. Generex Company Details
Table 148. Generex Business Overview
Table 149. Generex Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 150. Generex Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 151. Generex Recent Development
Table 152. Novavax, Inc. Company Details
Table 153. Novavax, Inc. Business Overview
Table 154. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 155. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 156. Novavax, Inc. Recent Development
Table 157. Sanofi Pasteur Company Details
Table 158. Sanofi Pasteur Business Overview
Table 159. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 160. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 161. Sanofi Pasteur Recent Development
Table 162. Baylor Company Details
Table 163. Baylor Business Overview
Table 164. Baylor Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 165. Baylor Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 166. Baylor Recent Development
Table 167. iBio, Inc. Company Details
Table 168. iBio, Inc. Business Overview
Table 169. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 170. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 171. iBio, Inc. Recent Development
Table 172. Moderna, Inc. Company Details
Table 173. Moderna, Inc. Business Overview
Table 174. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 175. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 176. Moderna, Inc. Recent Development
Table 177. Curevac Company Details
Table 178. Curevac Business Overview
Table 179. Curevac Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 180. Curevac Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 181. Curevac Recent Development
Table 182. ImmunoPrecise Company Details
Table 183. ImmunoPrecise Business Overview
Table 184. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 185. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 186. ImmunoPrecise Recent Development
Table 187. Novel Coronavirus (COVID-19) Vaccine Market Trends
Table 188. Novel Coronavirus (COVID-19) Vaccine Market Drivers
Table 189. Novel Coronavirus (COVID-19) Vaccine Market Challenges
Table 190. Novel Coronavirus (COVID-19) Vaccine Market Restraints
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Novel Coronavirus (COVID-19) Vaccine Product Picture
Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (US$ Million): 2018 VS 2023 VS 2033
Figure 3. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type: 2023 VS 2033
Figure 4. DNA Features
Figure 5. RNA Features
Figure 6. Others Features
Figure 7. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (US$ Million): 2018 VS 2023 VS 2033
Figure 8. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application: 2023 VS 2033
Figure 9. Mild Symptom Patient
Figure 10. Critically Ill Patient
Figure 11. Novel Coronavirus (COVID-19) Vaccine Report Years Considered
Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Revenue, (US$ Million), 2018 VS 2023 VS 2033
Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Size 2018-2033 (US$ Million)
Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Region: 2023 VS 2033
Figure 15. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region in 2018 VS 2023
Figure 16. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share Forecast by Region (2024-2033)
Figure 17. Global Top 10 Novel Coronavirus (COVID-19) Vaccine Countries Ranking by Market Size (US$ Million) in 2023
Figure 18. Global Novel Coronavirus (COVID-19) Vaccine Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Figure 19. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2023
Figure 20. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023
Figure 22. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Company in 2023
Figure 23. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 24. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 25. North America Novel Coronavirus (COVID-19) Vaccine Revenue Share by Country (2018-2033)
Figure 26. United States Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 27. Canada Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 28. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Company in 2023
Figure 29. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 30. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 31. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Share by Country (2018-2033)
Figure 32. Germany Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 33. France Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 34. U.K. Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 35. Italy Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 36. Russia Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 37. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Company in 2023
Figure 38. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 39. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 40. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Share by Region (2018-2033)
Figure 41. China Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 42. Japan Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 43. South Korea Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 44. India Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 45. Australia Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 46. China Taiwan Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 47. Indonesia Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 48. Thailand Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 49. Malaysia Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 50. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Company in 2023
Figure 51. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 52. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 53. Latin America Novel Coronavirus (COVID-19) Vaccine Revenue Share by Country (2018-2033)
Figure 54. Mexico Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 55. Brazil Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 56. Argentina Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 57. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Company in 2023
Figure 58. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2033)
Figure 59. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2033)
Figure 60. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Share by Country (2018-2033)
Figure 61. Turkey Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 62. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 63. UAE Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2033) & (US$ Million)
Figure 64. Inovio Pharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 65. Takis Biotech (Evvivax) Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 66. Zydus Cadila Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 67. Codagenix, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 68. GeoVax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 69. Bravovax Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 70. Janssen Pharmaceutical Companies Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 71. Altimmune Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 72. Vaxart Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 73. CanSino Biologics Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 74. ExpreS2ion Biotechnologies ApS Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 75. Clover Biopharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 76. GSK Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 77. Vaxil Bio Ltd. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 78. Generex Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 79. Novavax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 80. Sanofi Pasteur Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 81. Baylor Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 82. iBio, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 83. Moderna, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 84. Curevac Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 85. ImmunoPrecise Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed